Povofortay Wins EU Approval as First Once-Daily Oral HS Treatment
INCY sits 32% above its 52-week low of $89.25.
Summary
The European Commission approved Povofortay (povorcitinib) 45 mg and 75 mg for adults with moderate to severe hidradenitis suppurativa who have failed or cannot take anti-TNF therapy. It is the first once-daily oral treatment cleared in the EU for this disease, based on the Phase 3 STOP-HS1 and STOP-HS2 trials, where up to 71.4% of patients hit HiSCR50 through Week 54. CEO Bill Meury called it a key growth driver, and the approval gives Incyte a new commercial asset in Europe beyond its Jakafi-dependent hematology base. The bigger prize is still pending: the FDA is reviewing the same NDA, with U.S. approval and launch anticipated in the first quarter of 2027. This lands after the October 29 guidance raise to $5.21-$5.30 billion and the November 13 decision to drop the Phase 3 MAESTRA-3 ovarian cancer study, so it reinforces the inflammation and autoimmunity franchise as the growth story.
At the time of this announcement, INCY was trading at $117.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.5B. The 52-week trading range was $89.25 to $132.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.